Singapore, Oct. 27 -- The Health Sciences Authority received information related to the study titled 'A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants with Advanced Solid Tumors'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
Trial Status: NA
Principal Investigator(s):
Dr Darren Lim Wan Teck
Published by HT Digital Content Services with permission from Health Daily Digest....